Posted by Michael Wonder on 03 Oct 2022
Viewpoint Molecular Targeting announces VMT-alfa-NET granted US FDA fast track destination for the treatment of neuroendocrine tumours
3 October 2022 - Viewpoint Molecular Targeting today announced that the US FDA has granted fast track designation for the development of [212Pb]VMT-α-NET for treatment of patients with SSTR2 positive unresectable or metastatic neuroendocrine tumours (including GEP-NETs or bronchial NETs and pheochromocytomas and paragangliomas).
The Company's proprietary technology utilises the isotope lead-212 to deliver powerful alpha radiation specifically to cancer cells via specialised targeting peptides.
